Evidence map›Paper›PMID 42236548›Full record

ArticleThe EMBO journal2026

Alternative splicing broadens antiviral diversity at the human OAS2 locus.

Emma L Davies, Alegna Calderon Nuñez, Allison L Ward, Hanna Sowar, Eilidh Rivers, Arda Balci, Daniel Mair, Elliot Moorhouse, Jake Towers, Arthur Wickenhagen and 4 more

Abstract read
In one paragraph

Article in The EMBO journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Emma L DaviesMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK. emma.davies@glasgow.ac.uk.ORCID http://orcid.org/0000-0002-8416-9203
Alegna Calderon Nuñez *MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0009-0005-7666-4879
Allison L Ward *MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0009-0003-4604-7138
Hanna SowarMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK.
Eilidh RiversMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0009-0001-4084-3825
Arda BalciMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0003-1887-821X
Daniel MairMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK.
Elliot MoorhouseMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0009-0009-0810-3710
Jake TowersMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK.
Arthur WickenhagenMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0001-5470-1505
Matthew L TurnbullMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0002-7234-5871
Massimo PalmariniMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK.
Sam J WilsonCambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), University of Cambridge, Cambridge, UK. sjw58@cam.ac.uk.ORCID http://orcid.org/0000-0002-6065-0895
Adam J FletcherMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK. adam.fletcher@glasgow.ac.uk.ORCID http://orcid.org/0000-0003-1742-6588

Funding

UKRI | Medical Research Council (MRC) MC_ST_00034 StudentshipsUKRI | Medical Research Council (MRC) MC_UU_00034/3UKRI | Medical Research Council (MRC) MR/P022642/1,MR/V01157X/1UKRI | Medical Research Council (MRC) MR/T043482/1Wellcome TrustWellcome Trust (WT) 218518/Z/19/Z
6 · The paper itself

Abstract

Interferons (IFN) are cytokines that regulate the expression of hundreds of genes during viral infections to generate a broadly antiviral environment in the stimulated cell. Antiviral breadth is provided by the concurrent expression of many individual IFN-stimulated genes (ISG), each encoding a protein with often exquisite antiviral specificity. Here, we identify mechanistic plasticity at a single genetic locus as a novel mechanism to diversify the antiviral profile of human cells. Through alternative splicing, the OAS2 gene encodes two antiviral molecules with distinct target specificities. The shorter OAS2 p69 isoform restricts seasonal human coronavirus OC43 (HCoV-OC43), whereas the longer p71 isoform restricts picornavirus Cardiovirus A (EMCV). The restriction profile is determined by the variable length OAS2 C-terminal tails. Notably, these antiviral activities differ in their dependence on RNase L, suggesting that alternative splicing separates canonical restriction and virus sensing functions across two distinct OAS2 polypeptides. Together, these findings show how alternative splicing expands antiviral diversity at the human OAS2 locus.

Indexed as

2',5'-Oligoadenylate SynthetaseAlternative SplicingEncephalomyocarditis virusEndoribonucleasesHumansProtein Isoforms2-5A-dependent ribonuclease2',5'-Oligoadenylate SynthetaseEndoribonucleasesOAS2 protein, humanProtein Isoforms

Identifiers

PMID42236548
PMCPMC13372824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.